 |
|
Current Strategies for Management of Hypertensive Renal Disease
Michael A. Moore, MD;
Murray Epstein, MD;
Lawrence Agodoa, MD;
Lance D. Dworkin, MD
Arch Intern Med. 1999;159:23-28.
The incidence of hypertensive end-stage renal disease continues to increase annually. To reduce this incidence, it is necessary to control systolic and diastolic hypertension. Reversible causes should always be sought in any hypertensive patient who develops renal insufficiency. Blood pressure should be reduced to 130/85 mm Hg, and in African Americans with hypertensive renal failure, reducing the blood pressure to 120/75 mm Hg may be beneficial. Any antihypertensive treatment regimen that effectively lowers blood pressure will help slow progressive renal failure. Whenever possible, an angiotensin-converting enzyme inhibitor should be part of the treatment, since these drugs have been shown to be renoprotective beyond their antihypertensive effect in certain renal disease categories.
From the Danville Urologic Clinic, Danville, Va (Dr Moore); Nephrology Section, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC (Dr Moore); Nephrology Service, Veterans Affairs Medical Center, Miami, Fla (Dr Epstein); Minority Health Programs, National Institute of Diabetes, Digestive, and Kidney Diseases, National Institutes of Health, Bethesda, Md (Dr Agodoa); and Division of Renal Disease, Rhode Island Hospital, Providence (Dr Dworkin).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
The role of arterial hypertension in the progression of non-diabetic glomerular diseases
Ljutic and Kes
Nephrol Dial Transplant 2003;18:v28-30.
ABSTRACT
| FULL TEXT
|
